Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBV Technologies has filed its first Annual Report on Form 10-K and its 2020 Universal Registration Document, both covering the fiscal year ended December 31, 2020. These filings are available on the company's website and regulatory authorities. Additionally, DBV will be included in the SBF 120 Index on Euronext starting March 22, 2021, which consists of the largest 120 companies by market capitalization. This inclusion reflects DBV’s growing stature within the market as it focuses on developing innovative therapies for food allergies through its Viaskin technology.
As of February 28, 2021, the company reported a total of 54,936,687 shares outstanding. The total number of voting rights is listed as 54,936,687 gross and 54,888,687 net. The net total accounts for shares without voting rights, offering a clear picture of shareholder influence. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies reported its 2020 financial results, revealing a net loss of $(159.6) million, improved from $(172.0) million in 2019. Operating income dropped 23.3% to $11.3 million, while operating expenses decreased to $170.1 million due to cost-cutting measures. DBV ended 2020 with cash equivalents of $196.4 million, supporting operations until at least mid-2022. Additionally, the company is advancing its Viaskin Peanut trials in the US and EU, positioning itself for potential approvals. DBV will host a conference call to discuss these developments.
DBV Technologies announced its participation in the H.C. Wainwright Global Life Sciences Conference taking place on March 9-10, 2021. CEO Daniel Tassé will present during the event. A webcast of the presentation will be available on the company’s website starting March 9 at 7:00 a.m. ET. DBV Technologies focuses on developing Viaskin™, a proprietary platform for epicutaneous immunotherapy, targeting food allergies, with ongoing trials for Viaskin Peanut. The company is headquartered in Montrouge, France, and trades on Euronext Paris (DBV) and Nasdaq (DBVT).
DBV Technologies has announced a rescheduling of its financial results conference call for the full year 2020, now set for March 11, 2021, at 5:00 PM ET. The call will provide a financial update and a corporate overview. The event can be accessed through various teleconferencing numbers and will also be available via a live webcast on the company’s website. DBV Technologies is focused on developing Viaskin™, an innovative immunotherapy platform aimed at addressing food allergies through epicutaneous delivery methods.
DBV Technologies will report its full year 2020 financial results on March 4, 2021. The clinical-stage biopharmaceutical company will hold a conference call and live audio webcast at 5:00 p.m. ET to discuss the results and provide a corporate update. Interested parties can access the call via specified teleconferencing numbers and also via a live webcast available on the company's website. The company is focused on developing Viaskin™, a proprietary technology for treating food allergies through a non-invasive method.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT) announced its participation in the AAAAI 2021 Congress from February 26 to March 1. The company will present findings from a post-hoc analysis of its 12-month Phase 3 PEPITES trial, focusing on the effectiveness of its DBV712 (Viaskin™ Peanut) patch in reducing allergic reactions in children aged 4 to 11. They will also showcase pre-clinical data regarding cashew allergies. Additionally, DBV is sponsoring the FIT Networking Lounge to foster connections among AAAAI fellows.
DBV Technologies has appointed Michele F. Robertson as the new Chief Legal Officer, effective immediately. She brings over 15 years of legal expertise in the biopharma sector, previously serving as General Counsel at Mallinckrodt Pharmaceuticals. Robertson will support DBV's scientific development, regulatory efforts, and corporate governance while facilitating interactions with the FDA. DBV aims to advance its Viaskin™ Peanut product, focusing on meeting the needs of food-allergic patients. The company is positioned for regulatory clarity and strategic growth.
DBV Technologies (Ticker: DBVT) announced CEO Daniel Tassé will participate in a virtual fireside chat at the SVB Leerink Global Partners Healthcare Conference on February 24, 2021, at 8 am ET. The event will be accessible via a live webcast on DBV's website, with a replay available post-event. The company is focused on developing Viaskin™, a proprietary technology for immunotherapy targeting food allergies, including ongoing trials for Viaskin Peanut. DBV Technologies operates globally, with headquarters in Montrouge, France, and offices in the USA.
As of January 31, 2021, the company reported a total of 54,929,187 shares outstanding. This includes 54,883,187 net voting rights, calculated by subtracting shares without voting rights from the total shares. This report adheres to Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.